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Abstract
Rationale Several studies have suggested that modulation
of the glutamatergic system could be a new, efficient way to
achieve antidepressant activity. Behavioral data showed that
group II mGlu receptor antagonists (i.e., (1R,2 R,3 R,5 R,
6R)-2-amino-3-(3,4-dichlorobenzyloxy)-6-fluorobicyclo
[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039) and
(2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xan
th-9-yl) propanoic acid (LY341495)) elicited antidepressant
activity in several animal models of depression in rats and/or
mice. Although the antidepressant-like activity of MGS0039
and LY341495 is well documented, the mechanism of the
antidepressant action of these compounds is still not clear.
Objectives The aim of the present study was to specify the
role of the serotonergic system in the mechanism of the
antidepressant-like activity of group II mGlu receptor
ligands by using the tail suspension test (TST) in mice;
the role of AMPA receptors was also investigated.
Furthermore, the possible antidepressant-like action of
MGS0039 using the olfactory bulbectomy (OB) model of
depression in rats was investigated.
Results The results of the TST studies showed that
antidepressant-like action of group II mGlu receptor
antagonists does not depend on serotonergic system
activation. However, the AMPA receptor seems to play a
key role in the antidepressant-like action of these compounds.
Moreover, we have shown that repeated administration of
MGS0039 attenuated OB-related deficits, confirming
antidepressant-like activity of the tested compound.
Conclusions The results suggest that the blockade of group
II mGlu receptors may be effective in the treatment of
depression. Moreover, we have found that the mechanism
of action of group II mGlu receptor antagonists differs from
that of typical antidepressants, such as SSRIs.
Keywords AMPA receptors.Antidepressant drugs.
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Introduction
Preclinical data has indicated that modulating the gluta-
matergic system might be an alternative, efficient method to
achieve an antidepressant effect (Pałucha and Pilc 2007;
Pilc et al. 2008; Skolnick et al. 2009; Wierońska and Pilc
2009). Two types of glutamatergic receptors are responsible
for the regulation of glutamatergic neurotransmission:
ionotropic glutamate receptors (iGlu receptors), including
NMDA, AMPA, a kainate receptors, and metabotropic
glutamate receptors (mGlu receptors) composed of eight
mGlu receptor subtypes (mGlu1–mGlu8 receptors), divided
into three groups: group I (mGlu1 and mGlu5 receptors),
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DOI 10.1007/s00213-010-1978-5group II (mGlu2 and mGlu3 receptors), and group III
containing mGlu4, mGlu6, mGlu7, and mGlu8 receptors
(Conn and Pin 1997). Some data collected from the last few
years have indicated that ligands of mGlu receptors,
particularly antagonists of mGlu5 receptors and antagonists
of group II mGlu receptors, produced antidepressant-like
effects in rodent models of depression (Pałucha and Pilc
2007).
Among group II mGlu receptor ligands, MGS0039
(Chaki et al. 2004) and LY341495 (Ornstein et al. 1998)
have been best characterized as potential antidepressants.
Behavioral studies showed that both compounds elicited
antidepressant activity in the tail suspension test (TST), in
the rat forced swim test (FST) (Chaki et al. 2004), and the
learned helplessness paradigm in rats (Yoshimizu et al.
2006). Furthermore, MGS0039 has been reported to
increase cell proliferation in the adult mouse hippocampus
after 2 weeks administration (Yoshimizu and Chaki 2004).
It is proposed that neurogenesis is related to the mechanism
of action of antidepressant drugs, and the behavioral effects
of antidepressants were shown to be correlated with the
stimulation of neurogenesis in the adult hippocampus
(Santarelli et al. 2003). Thus, the MGS0039-promoted
proliferation of hippocampal neurons may be additional
evidence for the support of antidepressant-like activity of
group II mGlu receptor antagonists.
Although the antidepressant activity of MGS0039 and
LY341495 is well documented, the mechanism of the
antidepressant action of these compounds is still not clear.
Some data has indicated that the mechanism of the
antidepressant-like activity of group II mGlu receptor
antagonists might be related to serotonergic system regula-
tion. Firstly, it was shown that the application of mGlu2/3
receptor antagonists stimulated the activity of serotonergic
neurons in the dorsal raphe nucleus and increased extracel-
lular concentration of serotonin in the medial prefrontal
cortex in freely moving rats (Karasawa et al. 2005;
Kawashima et al. 2005). Therefore, the activation of seroto-
nergic neurotransmissions may be responsible for the
antidepressant-like activity of group II mGlu receptor antag-
onists. Secondly, when a modified version of the FST was
used to determine the antidepressant-like profile of MGS0039
and LY341495 in rats, i.e., three parameters were measured
(climbing, swimming, and immobility), both compounds
induced an increase in swimming behavior and a decrease in
immobility without affecting the climbing behavior, similar to
a reference antidepressant drug, fluvoxamine (Chaki et al.
2004). Such a pattern of activity in the FST suggests
serotonin-dependent mechanism of antidepressant-like activity
of mGlu2/3 receptor antagonists (Detke et al. 1995).
Furthermore, pretreatment with AMPA receptor antago-
nist, NBQX (2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]
quinoxaline-7-sulfonamide), attenuated the increase in
serotonin release by MGS0039 in the rats' medial prefrontal
cortex, and, on the other hand, NBQX prevented the
antidepressant-like effect of MGS0039 in the TST. There-
fore, it seems that AMPA receptors played a role in the
mechanism of action of MGS0039 in the TST (Karasawa et
al. 2005).
Thus, we decided to assess the role of the serotonergic
system in the mechanism of antidepressant-like activity of
group II mGlu receptor ligands and to investigate other
possible mechanisms responsible for the antidepressant-like
action of MGS0039 and LY341495, including the involve-
ment of AMPA receptors, by using the TST in mice.
Furthermore, the possible antidepressant-like action of
MGS0039 using the olfactory bulbectomy (OB) model
of depression in rats was investigated. The OB model of
depression has been previously used to assess a series of novel
potential antidepressant drugs, including those acting via the
glutamatergic system, such as the NMDA receptor antagonist,
dizocilpine (Redmond et al. 1997)o rm G l u 5r e c e p t o r
antagonists such as MTEP or MPEP (Pałucha et al. 2005;
Pilc et al. 2002) or GABAB receptor antagonists (Nowak et
al. 2006). Therefore, it seems that the OB model of depression
appears to be useful to also investigate the antidepressant-like
effects of the group II mGlu receptor antagonist.
Materials and methods
Animals and housing
Male Sprague–Dawley rats (Charles River, Germany),
weighing 250–270 g, were used to assess antidepressant-
like effects in the OB model of depression, while male
C57BL/6J mice (IF PAN breeding facility), weighing 23–
25 g, were used in the TST. The animals were kept under
standard laboratory conditions of lighting (light phase
7:00–19:00) and temperature (19–21°C). Food and water
were freely available. Each experimental group consisted of
seven to nine animals. All the subjects were experimentally
naive and used only once in each test, apart from the OB
rats, which were used in the open field test and 2 days later
in the passive avoidance test. Experiments were performed
during the light period (9:00–14:00 h) by an observer
unaware of the treatment. All procedures were conducted
according to the guidelines of the National Institutes of
Health Animal Care and Use Committee and were
approved by the Ethics Committee of the Institute of
Pharmacology, Polish Academy of Sciences in Kraków.
Drug administration
MGS0039 (Taisho Pharmaceutical Co., Ltd.,Saitama, Japan),
LY341495 (Tocris Cookson Ltd., Bristol, UK), ritanserin
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Cookson Ltd., Bristol, UK), and para-chlorophenylalanine
(PCPA) (Sigma-Aldrich, St. Louis, USA) were dispersed in a
suspension of 0.5% methylcellulose, which was used as a
vehicle. WAY100635 (N-{2-{4-(2-methoxyphenyl)-1-
piperazinyl}ethyl}-N-(2-pyridinyl) cyclo-hexanecarbox-
amide fumarate) (Sigma-Aldrich, St. Louis, USA) and
NBQX disodium salt (Ascent scientific Ltd., Bristol,
UK) were dissolved in sterile water. Amitriptyline
(Sigma-Aldrich, St. Louis, USA) was soluble in 0.9%
NaCl. In mice, MGS0039 and LY341495 were administered
intraperitoneally (IP) 30 min before the test. Metergoline and
ritanserin were given IP, 60 min before the experiment.
WAY100635 and NBQX were administered subcutaneously
(SC), 45 and 35 min, respectively, before the test. In the OB
studies in rats, the administration of the drugs began 2 weeks
after surgery. Amitriptyline (10 mg/kg, IP) and MGS0039 (1
and 3 mg/kg, IP) were given for 14 days, once daily, between
8:00and10:00a.m.,24hafterthelastdoseopenfieldtestwas
done. Drugs were administered after the test and the day after.
The passive avoidance test was performed 2 days after the
open field test, 24 h after the drugs' administration.
Olfactory bulbectomy
Surgical procedure
Using our published standard procedure (Pałucha et al.
2005; Wierońska et al. 2002) the following, to summarize it
here only briefly, was done: 1 week after arrival in the
laboratory, a bilateral olfactory bulbectomy was performed
on rats under a ketamine (100 mg/kg)/xylazine (10 mg/kg)
anesthesia. Metoxicam (0.05 mg/kg, SC) was given as an
analgesic and anti-inflammatory drug 60 min both before
the operation and the following 2 days after the surgery.
Following exposure of the skull, burr holes were drilled
using the coordinates 7 mm anterior to the bregma and
2 mm (on either side) from the middle line, i.e., at a point
corresponding to the posterior margin of the orbit of the
eye. The olfactory bulbs were removed by suction, and the
burr holes were filled with a haemostatic sponge (Ferrosan,
Poland). The skin was closed. Sham-operated animals were
similarly treated, but the bulbs were left intact. The animals
were allowed to recover for 14 days following surgery; they
were handled daily by the experimenter throughout the
recovery period to eliminate any aggressiveness that would
otherwise develop (Leonard and Tuite 1981).
Open field
The open field test was performed using an “open field”
apparatus consisting of an arena 90 cm in diameter which
was divided into 10 cm squares by faint yellow lines. The
field was surrounded by a 75-cm high aluminum sheet.
Illumination was provided by a 60-W bulb, which was
positioned 90 cm above the floor. All measurements were
carried out in a darkened room. The animals were
individually placed in the center of the open field and
allowed to freely explore for 3 min. The behaviors of
interest were the episodes of rearing, defined as raising the
forepaws from the floor, and ambulation, i.e., the number of
sector lines crossed (once a line had been crossed with all
four paws).
Passive avoidance paradigm
The passive avoidance test was performed using an open
box (55×35×20 cm) with black walls and a stainless steel
grid floor. The rods were 1 and 2 cm apart and were
connected to the terminals of the stimulator delivering a
square wave pulse. The delivered shock had a constant
intensity (0.75 mA) and lasted for 1 s. A wooden platform
measuring 12×12×3 cm was positioned in the center of the
box onto which each rat was initially placed. Once the rat
left the platform with all four paws it received an electric
shock. The animals were immediately removed from the
experimental cage and transferred to the home cage. The
next trial was initiated after a 30-s interval. The experiment
was stopped once the rat had learned to stay on the platform
for 1 min.
Lesion verification
Rats were sacrificed after all experimental procedures had
been performed. The brains were rapidly removed and
examined for signs of cortical damage or incomplete
removal of olfactory bulbs. Such animals were excluded
from the data analysis.
Tail suspension test
Immobility was induced by tail suspension according to the
procedure of Steru et al. (1985). C57BL/6J mice were
individually suspended by their tails by a plastic string
positioned horizontally 75 cm above the tabletop using
adhesive tape placed about 1 cm from the tip of the tail. The
immobility duration was recorded for 6 min. Mice were
considered immobile only when they hanged down passively
and were completely motionless.
Locomotor activity test in mice
The spontaneous locomotor activity of mice was measured
in Plexiglas locomotor activity chambers (40×20×15 cm)
in a 20-station photobeam activity system (Opto-M3
Activity Meter, Columbus Instruments, USA) where the
Psychopharmacology (2010) 212:523–535 525animals were placed individually 30 min after the injection
of MGS0039. The total number of ambulations was
recorded for 30 min and stored every 5 min.
5HT depletion
To deplete 5HT, mice were pretreated with the tryptophan
hydroxylase inhibitor, PCPA (300 mg/kg), which was given
IP, at a dose of 300 mg/kg. Injections were made twice
daily (at 9:00 a.m. and at 18:00), for three consecutive days.
Experiments were made on the fourth day and started at
10:00 a.m.
Statistical analysis
The data was presented as the means ± SEM and evaluated
by the two-way ANOVA followed by Bonferroni's post hoc
test (TST) or the repeated measure ANOVA followed by
Dunnett's test (locomotor activity). GraphPad Prism version
4.00 for Windows 2000 (GraphPad Software, San Diego
CA, USA) was used to analyze the data.
The results of the OB experiments were analyzed by
factorial ANOVA followed by LSD post hoc comparison
with the use of STATISTICA ver. 8.0 software.
Results
Effects of MGS0039 in the olfactory bulbectomy model
of depression
Open field
The analysis of the results of the ambulation scores with
ANOVA revealed a significant group [F(1,24)=4.47], treat-
ment [F(1,24)=5.5], and the group×treatment interaction in
all experimental groups [F(1,24)=9.12] (Fig. 1a).
LSD post hoc analysis showed a significant lesion effect
in the vehicle-treated animals (p<0.00001). The significant
treatment effect was observed in amitriptyline (AMI)-
treated groups, where the attenuation of the OB-induced
deficit was observed (p<0.001). The analysis that included
the two doses of MGS0039 also revealed a significant
lesion×treatment interaction (p<0.001) (Fig. 1a).
The analysis of the results of rearings with ANOVA
revealed a significant group [F(1,24)=17.54], treatment [F
(1,23)=23.66], and the group×treatment interaction in all
experimental groups [F(1,24)=2.7] (Fig. 1b).
LSD post hoc analysis showed a significant lesion effect
in the vehicle-treated animals (p<0.00001). The significant
treatment effect was observed in AMI-treated groups,
where the attenuation of OB-induced deficit was observed
(p<0.0001). In the analysis that included two doses of
MGS0039, it was also revealed that there was a significant
lesion×treatment interaction (p<0.001 and p<0.0001 for 1
and 3 mg/kg of MS0039, respectively) (Fig. 1b).
Passive avoidance paradigm
The analysis of the results of the passive avoidance
procedure with two-way ANOVA revealed a significant
group [F(1,24)=22.8], treatment [F(1,24)=24.6], and the
group×treatment interaction in all experimental groups
[F(1,24)=28.5] (Fig. 2).
LSD post hoc analysis showed a significant lesion effect
in the vehicle-treated animals (p<0.00001). The significant
treatment effect was observed in AMI-treated groups,
where the attenuation of the OB-induced deficit was
observed (p<0.00001). In the analysis that included two
Fig. 1 The effect of amitriptyline (AMI; 10 mg/kg, IP) and MGS0039
(1 and 3 mg/kg, IP) on the ambulatory movement (a) and the number
of rearings (b) in the OB model of depression. Rats were
administrated for 14 days with each compound in each group. At
24 h following the last treatment, ambulatory scores were measured in
the “open field”. Data from the session is expressed as mean and SEM
and analyzed using two-way ANOVA followed by the Fisher LSD
test. #p<0.00001 vs. sham/vehicle group; *p<0.001, **p<0.0001 vs.
OB/vehicle group. Six to seven animals per group were used
526 Psychopharmacology (2010) 212:523–535doses of MGS0039, it was also revealed that there was a
significant lesion×treatment interaction (p<0.00001 for 1
and 3 mg/kg). Moreover, a significant difference between
sham and OB animals receiving the MGS0039 in a dose of
3 mg/kg was observed (p<0.001) (Fig. 2).
Effects of antagonists of 5HT receptors
on the antidepressant-like activity of MGS0039 in the TST
MGS0039, administered at a dose of 3 mg/kg, decreased
the immobility time of C57BL/6J mice in the TST by about
66%. An antagonist of the 5HT1A receptor, WAY100635
(0.1 mg/kg), given alone, did not change the behavior of
animals in this test and it did not significantly influence the
antidepressant-like effect of MGS0039 [F(1,24)=0.07, p=
0.7927] (Fig. 3a).
MGS0039wasnotactiveintheTSTatadoseof0.3mg/kg.
Two-way ANOVA revealed that WAY100635 (0.1 mg/kg)
showed the tendency to enhance the non-active dose of
MGS0039 (0.3 mg/kg), although the effect was not statisti-
cally significant, [F(1,24)=2.115, p=0.158] (Fig. 3b).
The5HT2A/2Creceptorantagonist,ritanserin(0.5mg/kg),
was not active in the TST when given alone, and it did not
Fig. 2 The effect of amitriptyline (AMI; 10 mg/kg, IP) and MGS0039
(1 and 3 mg/kg, IP) in the passive avoidance paradigm in the OB
model of depression. Rats were administrated for 14 days with each
compound in each group. At 24 h following the last treatment, the
number of scores was measured in the passive avoidance paradigm.
Data from the session is expressed as mean and SEM and analyzed
using two-way ANOVA followed by the Fisher LSD test. #p<0.00001
vs. sham/vehicle group; *p<0.00001 vs. OB control group. Seven
animals per group were used
 Fig. 3 a The effect of WAY100635 (0.1 mg/kg) on the
antidepressant-like activity of MGS0039 (3 mg/kg) in the TST in
mice. Mice were pretreated with WAY100635 and with MGS0039,
respectively, 45 and 30 min before the test. Values are expressed as the
means ± SEM and analyzed by two-way ANOVA followed by
Bonferroni's post hoc test, ***p<0.001 vs. control group. b The effect
of WAY100635 (0.1 mg/kg) on the antidepressant-like activity of
MGS0039 (0.3 mg/kg) in the TST in mice. Mice were pretreated with
WAY100635 and with MGS0039, respectively, 45 and 30 min before
the test. Values are expressed as the means ± SEM and analyzed by
two-way ANOVA followed by Bonferroni's post hoc test. c The effect
of ritanserin (0.5 mg/kg) on the antidepressant-like activity of
MGS0039 (3 mg/kg) in the TST in mice. Mice were pretreated with
ritanserin and with MGS0039, respectively, 60 and 30 min before the
test. Values are expressed as the means ± SEM and analyzed by two-
way ANOVA followed by Bonferroni's post hoc test, ***p<0.001 vs.
control group. Seven animals per group were used
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immobility time in the TST in mice [F(1,24)=0.2868, p=
0.5972] (Fig. 3c).
Effects of antagonists of 5HT receptors
on the antidepressant-like activity of LY341495 in the TST
LY341495, given at a dose of 1 mg/kg decreased the
immobility time of the C57BL/6J mice in the TST by about
70%. An antagonist of the 5HT1A receptor, WAY100635
(0.1 mg/kg), given alone, did not change the behavior of the
animals in this test, and it did not significantly influence the
antidepressant-like effect of LY341495 [F(1,27)=0.1255, p=
0.7259] (Fig. 4a). The 5HT2A/2C receptor antagonist,
ritanserin (0.5 mg/kg), was not active in the TST when
given by itself, and it did not influence the LY341495-
induced attenuation of the immobility time in the TST in
mice [F(1,27)=1.099, p=0.3037] (Fig. 4b). Furthermore, the
5HTantagonist metergoline (0.5 mg/kg), given by itself, was
not active in the TST, and it did not significantly influence
the antidepressant-like effect of LY341495 [F(1,26)=0.3402,
p=0.5647] (Fig. 4c).
The effect of the AMPA receptor antagonist
on the antidepressant-like activity of MGS0039 in the TST
The AMPA receptor antagonist, NBQX, given at a dose of
10 mg/kg did not change the behavior of mice in the TST,
although it antagonized an antidepressant-like effect of
MGS0039 given at a dose of 3 mg/kg [F(1,24)=5.907, p=
0.0229] (Fig. 5).
Effects of serotonin depletion on the antidepressant-like
activity of citalopram and MGS0039 in the TST
Pretreatment with PCPA did not alter the baseline
immobility of mice. Citalopram, used as a reference
drug, at a dose of 20 mg/kg significantly decreased the
immobility time of mice in the TST [F(1,26)=61.67, p<
0.0001]. Two-way ANOVA revealed a significant interac-
tion between pretreatment with PCPA and citalopram
administration [F(1,26)=27.45, p<0.0001], showing that
citalopram was not active in the TST in the serotonin-
depleted mice (Fig. 6a).
MGS0039, at a dose of 3 mg/kg, was active in the
TST in both control and PCPA-pretreated mice [F(1,26)=
132.4, p<0.0001]. Two-way ANOVA also showed a
significant interaction between pretreatment with PCPA
and MGS0039 administration [F(1,26)=4.477, p<0.0441],
suggesting that the antidepressant-like activity of
M G S 0 0 3 9i ns e r o t o n i n - d e p l e ted mice was increased in
comparison to the control group not treated with PCPA
(Fig. 6b).
Fig. 4 The effect of WAY100635 (0.1 mg/kg) (Fig. 2a), ritanserin
(0.5 mg/kg) (Fig. 2b), or metergoline (0.5 mg/kg) (Fig. 2c) on the
antidepressant-like activity of LY341495 (1 mg/kg) in the TST in
mice. WAY100635 was given 45 min, ritanserin 60 min, metergoline
60 min, and LY341495 30 min before the test. Values are expressed as
the means ± SEM and analyzed by two-way ANOVA followed by
Bonferroni's post hoc test, ***p<0.001 vs. control group. Seven to
eight animals per group were used
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on the antidepressant-like activity of MGS0039
in serotonin-depleted mice in the TST
AMPA receptor antagonist, NBQX, given at a dose of
10 mg/kg, did not alter the baseline immobility of PCPA-
pretreated mice. MGS0039, given at a dose of 3 mg/kg,
induced an antidepressant-like effect in PCPA-pretreated
mice [F(1,24)=75.14, p<0.0001], and this effect was not
blocked by NBQX, given at a dose of 10 mg/kg [F(1,24)=
1.479, p=0.2357] (Fig. 7a). Subsequent experiments con-
firmed that MGS0039, at a dose of 3 mg/kg, decreased the
immobility time in 5HT-depleted animals in the TST. Two-
way ANOVA showed that this effect was antagonized by
NBQX, administered at a dose of 20 mg/kg [F(1,26)=
6.853, p=0.0146], which did not change the behavior of
mice, when it was given by itself (Fig. 7b).
The effects of antagonists of the 5HT receptors
and MGS0039 on the locomotor activity of mice
MGS0039, at a dose of 3 mg/kg, did not induce changes in
the locomotor activity of mice [F(1,60)=0.2384, p=
0.6341], although a significant effect of time on the
parameter [F(5,60)=61.18, p<0.0001] was observed.
WAY100635, at a dose of 0.1 mg/kg, did not influence
the basal locomotor activity of mice [F(1,60)=3.337, p=
0.0927]. Mice injected with MGS0039 co-administered
with WAY100635 were statistically less active in the
locomotor activity test than control animals (the curves
were significantly different) [F(1,60)=23.87, p=0.0004].
Post hoc analysis revealed that MGS0039+WAY100635
decreased basal locomotor activity at the first time point of
5 min (p<0.05), suggesting decreased exploratory activity.
Furthermore, there was a significant influence of MGS0039
on the locomotor activity of WAY100635-treated animals
(curves “WAY100635” and “WAY100635+MGS0039”
were significantly different) [F(1,60)=15.82, p=0.0018]
(Fig. 8a).
When WAY100635 (0.1 mg/kg) was co-administered
with a lower dose of MGS0039 (0.3 mg/kg), no changes in
locomotor activity were observed compared to the control
group (Fig. 8b).
Ritanserin, given at a dose of 0.5 mg/kg, did not
influence the basal locomotor activity of mice [F(1,60)=
1.059, p=0.3238]. MGS0039, at a dose of 3 mg/kg, similar
to the previous experiment, did not induce significant
Fig. 6 The effects of serotonin depletion on the antidepressant-like
activity of citalopram (Fig. 7a) or MGS0039 (Fig. 7b) in the TST in
mice. Values are expressed as the means ± SEM and analyzed by two-
way ANOVA followed by Bonferroni's post hoc test. ***p<0.001 vs.
vehicle+vehicle-treated group, ##p<0.001 vs. MGS0039-treated
group. Seven to eight animals per group were used
Fig. 5 The effect of NBQX (10 mg/kg) on the antidepressant-like
activity of MGS0039 (3 mg/kg) in the TST in mice. NBQX and
MGS0039 were given, respectively, 35 and 30 min before the test.
Values are expressed as the means ± SEM and analyzed by two-way
ANOVA followed by Bonferroni's post hoc test. ***p<0.001 vs.
control group, #p<0.05 vs. MGS0039-treated group. Seven animals
per group were used
Psychopharmacology (2010) 212:523–535 529changes in the locomotor activity of the animals. However,
locomotor activity of the mice administered with ritanserin
and MGS0039 was significantly decreased, compared to the
control group [F(1,60)=10.46, p=0.0072]. Post hoc anal-
ysis revealed that MGS0039+WAY100635 did not de-
crease basal locomotor activity at first two time points of 5
and 10 min (p<0.05), suggesting that exploratory activity
was not changed (p>0.05) (Fig. 8c).
The effect of the AMPA receptor antagonist and MGS0039
on the locomotor activity of mice
NBQX, given at a dose of 10 mg/kg, did not induce any
changes in the locomotor activity of mice [F(1,60)=
0.0003507, p=0.98]. MGS0039 (3 mg/kg), given alone or
in combination with NBQX, did not influence the
locomotor activity of mice [F(1,60)=3.374, p=0.0911]
(Fig. 8d).
Effect of citalopram and MGS0039 on the locomotor
activity of both 5HT-depleted and control mice
Citalopram, given at a dose of 20 mg/kg, did not influence
the locomotor activity of vehicle-treated mice [F(1,60)=
1.127, p=0.3093]. PCPA-pretreated animals were less
active in the locomotor activity test than vehicle-
pretreated mice (the curves were significantly different) [F
(1,60)=9.428, p=0.0097]. A similar effect was observed in
mice administered with citalopram, i.e., the locomotor
activity of PCPA-pretreated mice was decreased when
compared to vehicle-pretreated animals [F(1,60)=15.90,
p=0.0018] (Fig. 9a).
MGS0039, administered at a dose of 3 mg/kg, did not
change the locomotor activity of vehicle-pretreated mice [F
(1,60)=0.2948, p=0.5971]. However, in PCPA-pretreated
animals, MGS0039 induced a significant increase in the
locomotor activity of mice [F(1,60)=16.98, p=0.0014]
(Fig. 9b).
Discussion
The aim of the present study was to investigate the potential
antidepressant-like activity of a group II mGlu receptor
antagonist, MGS0039, in the OB model of depression in
rats and to assess the mechanism of antidepressant-like
activity in the TST in C57BL/6J mice.
A surgical lesion of the olfactory bulbs in animals
induces significant behavioral, physiological, endocrine and
immune changes, many of which were qualitatively similar
to those observed in depressive patients (for review see
Kelly et al. 1997). In animal studies, a variety of OB-related
behavioral changes, including hyperactivity in the “open
field” and deficiency in passive avoidance, responded
selectively to antidepressant treatment. Hyperactivity in
the “open field” always responds to chronic treatment with
antidepressants, mimicking the clinical lag-time of currently
used antidepressant drugs (Harkin et al. 2003). We used
both tests to evaluate a potential antidepressant-like effect
of MGS0039 in the OB model of depression in rats.
Repeated administration of MGS0039 attenuated the
hyperactivity of OB rats in the open field test and
attenuated the learning deficit in the passive avoidance
experiment, in the manner similar to that seen following
chronic treatment with a typical antidepressant, amitripty-
line, which was used for positive control. We also found
that the administration of group II mGlu receptor antagonist
did not result in any behavioral changes in the sham-
operated groups, indicating that its effect in OB rats was not
due to a stimulant or sedative effect of that compound.
MGS0039-induced changes in the behavior of OB rats may
be additional evidence for the support of antidepressant-like
Fig. 7 The effects of AMPA receptor antagonist, NBQX (10 mg/kg)
(Fig. 8a) or NBQX (20 mg/kg) (Fig. 8b) on the antidepressant-like
activity of MGS0039 (3 mg/kg) in serotonin-depleted mice in the TST.
Values are expressed as the means ± SEM and analyzed by two-way
ANOVA followed by Bonferroni's post hoc test. ***p<0.001 vs.
vehicle+vehicle-treated group, #p<0.05 vs. MGS0039-treated group.
Seven to eight animals per group were used
530 Psychopharmacology (2010) 212:523–535activity of group II mGlu receptor antagonists. However, it
must be remembered, that agonists of group II mGlu
receptors were shown to produce a number of desirable
effects, such as anti-seizures, neuroprotective, and antipsy-
chotic effects (Conn et al. 2009; Flor et al. 2002;
Klodzinska et al. 2000; Ure et al. 2006). As such, the
application of antagonists of mGlu2/3 receptors may carry a
risk of undesirable side effects and must be further
investigated.
To investigate the mechanism of the antidepressant-like
activity of MGS0039, the TST was chosen in this study,
since it is widely used to determine behavioral effects of
typical antidepressant drugs influencing the serotonergic,
noradrenergic, and dopaminergic systems, as well as
atypical and new potential antidepressants, including mGlu
receptor ligands (Cryan et al. 2005). Here, we observed the
antidepressant-like activity of MGS0039 and another group
II mGlu receptor antagonist LY341495, after peripheral
administration in the TST in mice. Although the potential
antidepressant-like activity of group II mGlu receptor
antagonists seems to be well established, the mechanism
by which these compounds exhibit such effects is still
unclear. However, some data indicates that it may be related
to serotonergic system regulation (see “Introduction”), thus
resembling the mechanism of action of typical antidepres-
sants such as SSRIs.
Fig. 8 a The effect of WAY100635 (0.1 mg/kg) on the locomotor
activity of MGS0039 (3 mg/kg) in mice. WAY100635 and MGS0039
were administered, respectively, 45 and 30 min before the test. Values
expressed as the means ± SEM were evaluated by repeated measure
ANOVA. **p<0.01 vs. WAY100635-treated group and ***p<0.001
vs. control group (Dunnett's test). b The effect of WAY100635
(0.1 mg/kg) on the locomotor activity of MGS0039 (0.3 mg/kg) in
mice. WAY100635 and MGS0039 were administered, respectively, 45
and 30 min before the test. Values expressed as the means ± SEM
were evaluated by repeated measure ANOVA. c The effect of
ritanserin (0.5 mg/kg) on the locomotor activity of MGS0039 (3 mg/
kg) in mice. Ritanserin and MGS0039 were administered, respective-
ly, 60 and 30 min before the test. Values expressed as the means ±
SEM were evaluated by repeated measure ANOVA. *p<0.05 vs.
ritanserin-treated group and **p<0.01 vs. control group (Dunnett's
test). d The effect of NBQX (10 mg/kg) on the locomotor activity of
MGS0039 (3 mg/kg) in mice. NBQX and MGS0039 were adminis-
tered, respectively, 35 and 30 min before the test. Values expressed as
the means ± SEM were evaluated by repeated measure ANOVA. Six
animals per group were used
Psychopharmacology (2010) 212:523–535 531Therefore, we aimed to clarify the role of the serotoner-
gic system in the antidepressant-like action of mGlu2/3
receptor antagonists in the TST. Firstly, we investigated the
influence of the pretreatment of mice with specific
serotonergic receptors antagonists, such as the 5HT1A
receptor antagonist, WAY100635 (Forster et al. 1995), and
5HT2A/2C receptor antagonist, ritanserin (Hoyer et al.
1994), on the antidepressant-like activity of MGS0039 or
LY341495 in the TST. Secondly, an influence of MGS0039
on the immobility time in the TSTwas measured in C57BL/
6J mice after the pharmacological depletion of serotonin.
Several lines of evidence indicate the crucial role of both
5HT1A and 5HT2A receptors in the regulation of serotoner-
gic neurotransmission and the involvement of these receptors
in the mechanism of action of many classes of antidepressant
drugs, including SSRI, MAOI, and tricyclics (Hensler 2002;
Middlemiss et al. 2002). It was also shown that pretreatment
with antagonists of 5HT1A and 5HT2A receptors antago-
nized antidepressant-like activity of SSRIs in the TST in
mice (Miyata et al. 2004), suggesting that activation of both
receptors plays a key role in the action of compounds acting
via activation of the serotonergic system in this test. The
results of our studies show that pretreatment of mice with
WAY100635 or ritanserin did not influence an
antidepressant-like action of MGS0039 in the TST. Similar-
ly, the antidepressant-like activity of another group II mGlu
receptor antagonist, LY341495, was not changed in mice
pretreated with WAY100635 or ritanserin. Furthermore, the
antidepressant-like activity of LY341495 was not blocked by
metergoline, which is an antagonist of a wide spectrum of
serotonergic receptors, including 5HT1, 5HT2, 5HT1D,
5HT6, and 5HT7 (Hoyer et al. 1994). These results suggest
that activation of the serotonergic system is not required in
the antidepressant-like action of group II mGlu receptor
antagonists.
It has been shown that 5HT1A antagonists enhance
antidepressant-like activity of antidepressants acting via the
activation of the serotonergic system, when given at low,
sub-effective doses (Artigas et al. 1996). This effect
resulted probably from a blockade of 5HT1A autoreceptors
by 5HT1A antagonists and a subsequent increase in the
level of serotonin. Thus, the antagonists of 5HT1A
receptors synergistically potentiate the serotonin level,
increased by SSRIs (Romero et al. 1996). Our study shows
that the action of the group II mGlu receptors antagonist,
MGS0039, was not significantly potentiated by an antag-
onist of the 5HT1A receptor, WAY100635, further con-
firming that the mechanism of the antidepressant-like
activity of MGS0039 was not serotonin-dependent.
Locomotor activity studies showed that MGS0039,
WAY100635, or ritanserin given by themselves did not
change this parameter in mice, confirming that the
antidepressant-like action of MGS0039 was not due to
hyperlocomotion. However, in mice pretreated with
WAY100635 or ritanserin, MGS0039 significantly dimin-
ished locomotor activity, suggesting that the lack of
influence of serotonergic blockers on the action of
MGS0039 in the TST was not a false negative effect
resulting from their influence on the hyperlocomotion. On
the other hand, our locomotor activity results suggest the
existence of interaction between group II mGlu receptors
and serotonin 5HT1A and 5HT2A receptors. Functional
and structural interaction between mGlu2 and 5HT2A
receptors is well documented, and it is believed to be
implicated in psychosis (González-Maeso et al. 2008;
Kłodzińska et al. 2002; Marek et al. 2000). Moreover, the
anxiolytic-like activity of mGlu receptor ligands was shown
to be dependent on the activation of the serotonergic
receptors; e.g., the anxiolytic-like action of mGlu5 receptor
antagonist, MTEP, or group III mGlu receptor antagonist,
Fig. 9 The effects of citalopram (a) and MGS0039 (b) on the
locomotor activity of serotonin-depleted and control mice. Values
expressed as the means ± SEM were evaluated by repeated measure
ANOVA, **p<0.01 vs. respective control group (Dunnett's test).
Seven animals per group were used
532 Psychopharmacology (2010) 212:523–535CPPG, were blocked by 5HT2A/2C receptor antagonist,
ritanserin, while group III mGlu receptor agonist, ACPT-I,
did not display anxiolytic-like activity in mice pretreated
with 5HT1A receptor antagonist, WAY100635 (Stachowicz
et al. 2007a, 2007b, 2009), suggesting a functional
interaction between group I or III mGlu receptors and
serotonergic 5HT1A and 5HT2A/2C receptors in anxiety-
related mechanisms. Although our locomotor activity
results indicate on interaction between group II mGlu
receptors and 5HT1A or 5HT2A/2C receptors, it seems
that this interaction did not play a role in the antidepressant-
like activity of the glutamatergic and serotonergic antago-
nists tested in the TST.
It is worth mentioning that our results, showing no
changes in the locomotor activity of mice after admin-
istration of group II mGlu receptor antagonists, seem to
be opposite to other studies where it was reported that
the group II mGlu receptor antagonist LY341495 in-
creased the locomotor activity of mice (Bespalov et al.
2007; O'Neill et al. 2003). However, in these studies, an
influence of the compound on the locomotor activity of
habituated animals was investigated. In our studies,
animals were given an injection of MGS0039 in a home
cage, and 30 min later, they were put into actometers
before the locomotor activity was measured. This para-
digm showed an influence of tested compounds on
spontaneous locomotor activity in a new environment,
and the treatment schedule was adequate to that used in
the TST, where animals were given an MGS0039
injection, and after 30 min, they were hung for 5 min by
their tails.
In order to further investigate the role of serotonin in
the mechanism of the antidepressant-like activity of
g r o u pI Im G l ur e c e p t o ra n t a g o n i s t s ,w eu s e dP C P At o
achieve 5HT depletion. PCPA is a selective inhibitor of
tryptophan hydroxylase (Koe and Weissman 1966)a n d
has been shown to decrease the brain 5HT level by about
78%, after IP administration, at a dose of 300 mg/kg, twice
daily, for three consecutive days (O'Leary et al. 2007).
This schedule for the administration of PCPA was used to
investigate the role of serotonin in the antidepressant
activity of SSRIs in the TST in C57BL mice (O'Leary et
al. 2007). The results have clearly shown that citalopram
and fluoxetine were not active in the serotonin-depleted
mice, while in control groups of animals (not treated with
PCPA), both compounds induced a significant decrease in
the immobility time in the TST. Thus, in our study, we
used the same scheme of PCPA administration. We
confirmed that citalopram induced a significant antide-
pressant effect in vehicle-treated mice, decreasing the
immobility time. However, in a group of animals admin-
istered with PCPA, citalopram did not change the
immobility time of mice compared to that of a respective
control group, confirming that PCPA-induced 5HT deple-
tion was enough to inhibit the behavioral effect of a
compound selectively acting via serotonergic system
modulation. The profile of the action of MGS0039 was
therefore opposite to that of citalopram; its antidepressant-
like activity in serotonin-depleted animals was not
inhibited but significantly enhanced.
We also examined an influence of MGS0039 on
locomotor activity. The results clearly show that while
MGS0039, in a dose of 3 mg/kg, did not change the
locomotor activity of vehicle-treated mice, it induced a
significant hyperlocomotion of serotonin-depleted ani-
mals in the 30-min test, although it remained without a
significant influence during the first 5 min of the
locomotor activity test, i.e., the time adequate for the
duration of the TST. Thus, the hyperlocomotion induced
by MGS0039 in PCPA-pretreated mice seems not to be
the reason for the decreased immobility of mice in the
tail suspension test.
Our studies confirm the observation of Karasawa et al.
2005 that the antidepressant-like activity of MGS0039 was
dependent on AMPA receptor activation, as AMPA receptor
antagonist, NBQX, given at a dose of 10 mg/kg, prevented
its antidepressant-like activity in the TST. Interestingly, a
higher dose (20 mg/kg) of NBQX was necessary to block
the antidepressant-like activity of MGS0039 in PCPA-
treated mice. It can be speculated that an increased level of
AMPA receptors in PCPA-treated animals accounted for the
lesser ability of NBQX to block the antidepressant-like
effect induced by MGS0039 in PCPA-pretreated mice,
which may confirm the data of Shutoh et al. (2000)
showing an increased level of AMPA receptors in PCPA-
treated animals. Also, enhanced activity of MGS0039 in the
PCPA-pretreated mice is not specifically antidepressant like
it seems, but rather a false positive effect, resulting
probably from changes in AMPA receptor level.
Altogether, the results of our studies show that
MGS0039 was active in the OB model of depression,
suggesting that the prolonged blockade of mGlu2/3
receptor may be effective in the treatment of depression.
Furthermore, the results of our TST studies show that the
antidepressant-like action of group II mGlu receptor
antagonists does not depend on serotonergic system
activation, indicating that the mechanism of the action of
group II mGlu receptor antagonists differs from that of
typical antidepressants, such as SSRIs. Moreover, we
conclude that the AMPA receptor seems to play a key role
in the antidepressant-like action of these compounds.
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